Evaluation of inflammatory and hematological parameters in patients diagnosed with COVID-19.

INTRODUCTION: This study aims to research the effects of hematological and inflammatory parameters on the prognosis of COVID-19 disease and hospitalization duration. METHODOLOGY: One hundred and eighty-six patients with COVID-19 and a control group consisting of 187 healthy individuals were included in the study. Hematological variables and inflammatory parameters of the patients were recorded on the first and the fifth days of hospitalization. RESULTS: White blood cell count, lymphocyte count, and platelet count were statistically lower, and mean platelet volume (MPV), neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) levels were higher in the patient group compared to the control group. It was observed that the neutrophil count and MPV level were lower, and the platelet count and ferritin level were statistically higher on the fifth day of follow-up compared to the admission day. In contrast, there was a significantly positive correlation between the duration of hospitalization and the fifth day D-dimer (r = 0.546, p < 0.001) and ferritin (r = 0.568, p < 0.001); in addition, there was a negative correlation between the duration of hospitalization and admission day lymphocyte count and the fifth-day lymphocyte count. CONCLUSIONS: Increased levels of ferritin and D-dimer, and decreased count of lymphocytes are among the important factors affecting the duration of hospitalization for COVID-19 patients. Furthermore, we think that neutrophil count and MPV levels are low, and platelet count and ferritin levels are high during the disease. Therefore, these parameters can be used as prognostic indicators of the disease.

Which COVID-19 Patients Die in Intensive Care Unit (ICU) in Turkey

A comparison of deceased and surviving patients showed that being female, older than 62, and a smoker and having diabetes mellitus, hypertension, and/or coronary artery disease significantly increased mortality. Information about the patients' age, gender, comorbidities, duration of hospitalization, COVID-19-related lung tomography findings, hemogram parameters (white blood cell (WBC), neutrophil, lymphocyte, and platelet counts, haemoglobin level, neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte ratios (PLR), biochemical parameters, and ventilatory support [mechanical ventilation, non-invasive mechanical ventilation (NIMV), high-flow oxygen (HFNO)] were retrospectively accessed in the hospital records. Since the first COVID-19 case was admitted on 15 March, 2020, a total of 618 patients have been diagnosed with COVID-19 in our hospital. The comparison of the deceased and surviving patients also displayed that smoking (p=0.004), diabetes mellitus (p=0.007), hypertension (p=0.042), and coronary artery disease (p=0.049) statistically increased mortality. In our study, the comparison of the laboratory parameters of the deceased and surviving patients showed that the platelet (p=0.006), white blood cell (p=0.048), and neutrophil counts (p=0.033), and NLR (p=0.010) and PLR (p=0.033) were significantly higher in the deceased group compared to the surviving group.

COVID-19: "Soru Íşaretleri"

The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. Pandemi dışındaki dönemlerde mevcut olan viral pnömonilerin tamamı "PCR negatif, tomo uyumlu corona" olarak deǧerlendirildi. Bu durum nasıl açıklanabilir?

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.

BACKGROUND: CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey. METHODS: This was a double-blind, randomised, placebo-controlled phase 3 trial. Volunteers aged 18-59 years with no history of COVID-19 and with negative PCR and antibody test results for SARS-CoV-2 were enrolled at 24 centres in Turkey. Exclusion criteria included (but were not limited to) immunosuppressive therapy (including steroids) within the past 6 months, bleeding disorders, asplenia, and receipt of any blood products or immunoglobulins within the past 3 months. The K1 cohort consisted of health-care workers (randomised in a 1:1 ratio), and individuals other than health-care workers were also recruited into the K2 cohort (randomised in a 2:1 ratio) using an interactive web response system. The study vaccine was 3 µg inactivated SARS-CoV-2 virion adsorbed to aluminium hydroxide in a 0·5 mL aqueous suspension. Participants received either vaccine or placebo (consisting of all vaccine components except inactivated virus) intramuscularly on days 0 and 14. The primary efficacy outcome was the prevention of PCR-confirmed symptomatic COVID-19 at least 14 days after the second dose in the per protocol population. Safety analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04582344) and is active but no longer recruiting. FINDINGS: Among 11 303 volunteers screened between Sept 14, 2020, and Jan 5, 2021, 10 218 were randomly allocated. After exclusion of four participants from the vaccine group because of protocol deviations, the intention-to-treat group consisted of 10 214 participants (6646 [65·1%] in the vaccine group and 3568 [34·9%] in the placebo group) and the per protocol group consisted of 10 029 participants (6559 [65·4%] and 3470 [34·6%]) who received two doses of vaccine or placebo. During a median follow-up period of 43 days (IQR 36-48), nine cases of PCR-confirmed symptomatic COVID-19 were reported in the vaccine group (31·7 cases [14·6-59·3] per 1000 person-years) and 32 cases were reported in the placebo group (192·3 cases [135·7-261·1] per 1000 person-years) 14 days or more after the second dose, yielding a vaccine efficacy of 83·5% (95% CI 65·4-92·1; p<0·0001). The frequencies of any adverse events were 1259 (18·9%) in the vaccine group and 603 (16·9%) in the placebo group (p=0·0108) with no fatalities or grade 4 adverse events. The most common systemic adverse event was fatigue (546 [8·2%] participants in the vaccine group and 248 [7·0%] the placebo group, p=0·0228). Injection-site pain was the most frequent local adverse event (157 [2·4%] in the vaccine group and 40 [1·1%] in the placebo group, p<0·0001). INTERPRETATION: CoronaVac has high efficacy against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile. FUNDING: Turkish Health Institutes Association.

COVID-19: Questions

The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from the Hubei province in China in late 2019 demonstrates the epidemic potential of coronaviruses. The rapid spread of this virus across the world in only 2 months highlights the transmissibility of this family of viruses and the significant morbidity and mortality that they can cause. We highlight the current state of knowledge of coronavirus biology while answering questions concerning the current outbreak of SARS-CoV-2. (English) [ FROM AUTHOR] Çin'in Hubei eyaletinde 2019 yılının sonlarına doğru akut solunum sendromu olarak (SARS-CoV-2) ortaya çıkmış olması korona virüslerinin salgın potansiyelini ortaya koymuştur. Íki ay gibi kısa bir süre içinde hastalığın tüm dünyaya hızla yayılmış olması bulaştırıcılığı gösterirken ciddi morbidite ve mortalitenin ciddiyetini gözler önüne sermiştir. Mevcut soruları virüsün biyolojik özellikleri ile irdelemek gerekmektir. (Turkish) [ FROM AUTHOR] Copyright of Dicle Medical Journal / Dicle Tip Dergisi is the property of Dicle Tip Dergisi/ Dicle Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

Pandemi Döneminde COVID-19 Kliniği ile Başvuran ve Tesadüfen Tespit Edilen AIDS Olgusu

[...]the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the patients, following the recognition of pneumonia cases of unknown etiology on December 31, 2019, in Wuhan, China revealed a new type of coronavirus. The disease caused by that virus has subsequently been named COVID-19 (Coronavirus disease 2019) by the World Health Organization. In clinical practice, we encounter fever, shortness of breath, and radiological findings compatible with pneumonic infiltration in the bilateral lung parenchyma in both infections (PCP and COVID-19). Results of the laboratory testing were as follows: the blood glucose level 100 mg/dl, serum creatinine level 0,59 mg/dL, AST 46 U/L, ALT 17 U/L, LDH 1102 U/L, CRP 62 mg/l, D-dimer 954 mg/L, leucocytes 12.410 /mm3 (87,6% neutrophils;6,8% lymphocytes), hemoglobin 11.9 g/dL and platelet count 258000 /mm3.